IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer

ACS Nano

Volumn 9, Issue 8, 2015, Pages 7976-7991

  Zhou, Hongyu ^a   Qian, Weiping ^a   Uckun, Fatih M ^b   Wang, Liya ^a   Wang, Y Andrew ^c   Chen, Hongyu ^c   Kooby, David ^a   Yu, Qian ^a   Lipowska, Malgorzata ^a   Staley, Charles A ^a   Mao, Hui ^a   Yang, Lily ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c OCEAN NANOTECH LLC   (United States)

Author keywords

IGF1R targeted cancer therapy; image guided cancer therapy; MRI; orthotopic pancreatic cancer patient tissue derived xenografts; theranostic nanoparticles

Indexed keywords

BIOLOGICAL MATERIALS; CELL DEATH; CELL PROLIFERATION; CELLS; CHEMOTHERAPY; CYTOLOGY; MAGNETIC RESONANCE IMAGING; MEDICAL NANOTECHNOLOGY; NANOMAGNETICS; NANOPARTICLES; ONCOLOGY; PATIENT TREATMENT; TUMORS;

APOPTOTIC CELL DEATH; CANCER THERAPY; HISTOLOGICAL ANALYSIS; IMAGE GUIDED THERAPY; MAGNETIC IRON OXIDE NANOPARTICLES; PANCREATIC CANCERS; TARGETED CANCER THERAPY; TUMOR MICROENVIRONMENT;

DISEASES;

ANTINEOPLASTIC ANTIBIOTIC; CONTRAST MEDIUM; DOXORUBICIN; FERRIC ION; FERRIC OXIDE; MAGNETITE NANOPARTICLE; PROTEIN BINDING; RECOMBINANT PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG FORMULATION; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MOUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; SCID MOUSE; THERANOSTIC NANOMEDICINE; TUMOR VOLUME; ULTRASTRUCTURE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CONTRAST MEDIA; DOXORUBICIN; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FERRIC COMPOUNDS; GENE EXPRESSION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PROTEIN BINDING; RECEPTOR, IGF TYPE 1; RECOMBINANT PROTEINS; THERANOSTIC NANOMEDICINE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940121365     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/acsnano.5b01288     Document Type: Article

References (56)

1. Siegel, R.; Ma, J. M.; Zou, Z. H.; Jemal, A. Cancer Statistics, 2014 Ca-Cancer J. Clin. 2014, 64, 9-29 10.3322/caac.21208
2. Warshaw, A. L.; Fernandez-del castillo, C. Pancreatic Carcinoma N. Engl. J. Med. 1992, 326, 455-465 10.1056/NEJM199202133260706
3. Willett, C. G.; Czito, B. G.; Bendell, J. C.; Ryan, D. P. Locally Advanced Pancreatic Cancer J. Clin. Oncol. 2005, 23, 4538-4544 10.1200/JCO.2005.23.911
4. Whatcott, C.; Han, H.; Posner, R. G.; Von Hoff, D. D. Tumor-Stromal Interactions in Pancreatic Cancer Crit. Rev. Oncog. 2013, 18, 135-51 10.1615/CritRevOncog.v18.i1-2.80
5. Schober, M.; Jesenofsky, R.; Faissner, R.; Weidenauer, C.; Hagmann, W.; Michl, P.; Heuchel, R. L.; Haas, S. L.; Lohr, J. M. Desmoplasia and Chemoresistance in Pancreatic Cancer Cancers 2014, 6, 2137-54 10.3390/cancers6042137
6. Kleeff, J.; Beckhove, P.; Esposito, I.; Herzig, S.; Huber, P. E.; Lohr, J. M.; Friess, H. Pancreatic Cancer Microenvironment Int. J. Cancer 2007, 121, 699-705 10.1002/ijc.22871
7. Feig, C.; Gopinathan, A.; Neesse, A.; Chan, D. S.; Cook, N.; Tuveson, D. A. The Pancreas Cancer Microenvironment Clin. Cancer Res. 2012, 18, 4266-4276 10.1158/1078-0432.CCR-11-3114
8. Erkan, M.; Hausmann, S.; Michalski, C. W.; Fingerle, A. A.; Dobritz, M.; Kleeff, J.; Friess, H. The Role of Stroma in Pancreatic Cancer: Diagnostic and Therapeutic Implications Nat. Rev. Gastroenterol. Hepatol. 2012, 9, 454-467 10.1038/nrgastro.2012.115
9. Bergers, G.; Hanahan, D. Modes of Resistance to Anti-Angiogenic Therapy Nat. Rev. Cancer 2008, 8, 592-603 10.1038/nrc2442
10. Tredan, O.; Galmarini, C. M.; Patel, K.; Tannock, I. F. Drug Resistance and the Solid Tumor Microenvironment J. Natl. Cancer Inst. 2007, 99, 1441-1454 10.1093/jnci/djm135
11. Eck, W.; Craig, G.; Sigdel, A.; Ritter, G.; Old, L. J.; Tang, L.; Brennan, M. F.; Allen, P. J.; Mason, M. D. PEGylated Gold Nanoparticles Conjugated to Monoclonal F19 Antibodies as Targeted Labeling Agents for Human Pancreatic Carcinoma Tissue ACS Nano 2008, 2, 2263-2272 10.1021/nn800429d
12. Patra, C. R.; Bhattacharya, R.; Wang, E. F.; Katarya, A.; Lau, J. S.; Dutta, S.; Muders, M.; Wang, S. F.; Buhrow, S. A.; Safgren, S. L. et al. Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent Cancer Res. 2008, 68, 1970-1978 10.1158/0008-5472.CAN-07-6102
13. Yang, L. L.; Mao, H.; Wang, Y. A.; Cao, Z. H.; Peng, X. H.; Wang, X. X.; Duan, H. W.; Ni, C. C.; Yuan, Q. G.; Adams, G. et al. Single Chain Epidermal Growth Factor Receptor Antibody Conjugated Nanoparticles for in vivo Tumor Targeting and Imaging Small 2009, 5, 235-243 10.1002/smll.200800714
14. Chanda, N.; Kattumuri, V.; Shukla, R.; Zambre, A.; Katti, K.; Upendran, A.; Kulkarni, R. R.; Kan, P.; Fent, G. M.; Casteel, S. W. et al. Bombesin Functionalized Gold Nanoparticles Show in vitro and in vivo Cancer Receptor Specificity Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 8760-8765 10.1073/pnas.1002143107
15. Patra, C. R.; Bhattacharya, R.; Mukhopadhyay, D.; Mukherjee, P. Fabrication of Gold Nanoparticles for Targeted Therapy in Pancreatic Cancer Adv. Drug Delivery Rev. 2010, 62, 346-361 10.1016/j.addr.2009.11.007
16. Meng, H.; Xue, M.; Xia, T.; Ji, Z. X.; Tarn, D. Y.; Zink, J. I.; Nel, A. E. Use of Size and a Copolymer Design Feature To Improve the Biodistribution and the Enhanced Permeability and Retention Effect of Doxorubicin-Loaded Mesoporous Silica Nanoparticles in a Murine Xenograft Tumor Model ACS Nano 2011, 5, 4131-4144 10.1021/nn200809t
17. Meng, H.; Zhao, Y.; Dong, J. Y.; Xue, M.; Lin, Y. S.; Ji, Z. X.; Mai, W. X.; Zhang, H. Y.; Chang, C. H.; Brinker, C. J. et al. Two-Wave Nanotherapy To Target the Stroma and Optimize Gemcitabine Delivery To a Human Pancreatic Cancer Model in Mice ACS Nano 2013, 7, 10048-10065 10.1021/nn404083m
18. Prabhakar, U.; Maeda, H.; Jain, R. K.; Sevick-Muraca, E. M.; Zamboni, W.; Farokhzad, O. C.; Barry, S. T.; Gabizon, A.; Grodzinski, P.; Blakey, D. C. Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology Cancer Res. 2013, 73, 2412-2417 10.1158/0008-5472.CAN-12-4561
19. Jain, R. K.; Stylianopoulos, T. Delivering Nanomedicine to Solid Tumors Nat. Rev. Clin. Oncol. 2010, 7, 653-664 10.1038/nrclinonc.2010.139
20. Ouban, A.; Muraca, P.; Yeatman, T.; Coppola, D. Expression and Distribution of Insulin-Like Growth Factor-1 Receptor in Human Carcinomas Hum. Pathol. 2003, 34, 803-808 10.1016/S0046-8177(03)00291-0
21. Valsecchi, M. E.; McDonald, M.; Brody, J. R.; Hyslop, T.; Freydin, B.; Yeo, C. J.; Solomides, C.; Peiper, S. C.; Witkiewicz, A. K. Epidermal Growth Factor Receptor and Insulin like Growth Factor 1 Receptor Expression Predict Poor Survival in Pancreatic Ductal Adenocarcinoma Cancer 2012, 118, 3484-3493 10.1002/cncr.26661
22. Bergmann, U.; Funatomi, H.; Yokoyama, M.; Berger, H. G.; Korc, M. Insulin-Like Growth Factor-I Overexpression in Human Pancreatic Cancer, Evidence for Autocrine and Paracrine Roles Cancer Res. 1995, 55, 2007-2011
23. Zheng, D.; Golubovskaya, V.; Kurenova, E.; Wood, C.; Massoll, N. A.; Ostrov, D.; Cance, W. G.; Hochwald, S. N. A Novel Strategy to Inhibit FAK and IGF-1R Decreases Growth of Pancreatic Cancer Xenografts Mol. Carcinog. 2009, 49, 200-209 10.1002/mc.20590
24. Peled, N.; Wynes, M. W.; Ikeda, N.; Ohira, T.; Yoshida, K.; Qian, J.; Ilouze, M.; Brenner, R.; Kato, Y.; Mascaux, C. et al. Insulin-Like Growth Factor-1 Receptor (IGF-1R) as a Biomarker for Resistance to the Tyrosine Kinase Inhibitor Gefitinib in Non-small Cell Lung Cancer Cell. Oncol. 2013, 36, 277-288 10.1007/s13402-013-0133-9
25. Suda, K.; Mizuuchi, H.; Sato, K.; Takemoto, T.; Iwasaki, T.; Mitsudomi, T. The Insulin-Like Growth Factor 1 Receptor Causes Acquired Resistance to Erlotinib in Lung Cancer Cells with the Wild-Type Epidermal Growth Factor Receptor Int. J. Cancer 2014, 135, 1002-1006 10.1002/ijc.28737
26. Shao, N.; Lu, S.; Wickstrom, E.; Panchapakesan, B. Integrated Molecular Targeting of IGF1R and HER2 Surface Receptors and Destruction of Breast Cancer Cells using Single Wall Carbon Nanotubes Nanotechnology 2007, 18, 315101 10.1088/0957-4484/18/31/315101
27. Kristensen, C.; Wiberg, F. C.; Andersen, A. S. Specificity of Insulin and Insulin-Like Growth Factor I Receptors Investigated using Chimeric Mini-Receptors-Role of C-Teriminal of Receptor Alpha Subunit J. Biol. Chem. 1999, 274, 37351-37356 10.1074/jbc.274.52.37351
28. Yang, L.; Mao, H.; Cao, Z. H.; Wang, Y. A.; Peng, X. H.; Wang, X. X.; Sajja, H. K.; Wang, L. Y.; Duan, H. W.; Ni, C. C. et al. Molecular Imaging of Pancreatic Cancer in an Animal Model Using Targeted Multifunctional Nanoparticles Gastroenterology 2009, 136, 1514-1525 10.1053/j.gastro.2009.01.006
29. Kumagai, M.; Kano, M. R.; Morishita, Y.; Ota, M.; Imai, Y.; Nishiyama, N.; Sekino, M.; Ueno, S.; Miyazono, K.; Kataoka, K. Enhanced Magnetic Resonance Imaging of Experimental Pancreatic Tumor in vivo by Block Copolymer-Coated Magnetite Nanoparticles with TGF-beta Inhibitor J. Controlled Release 2009, 140, 306-311 10.1016/j.jconrel.2009.06.002
30. Loebinger, M. R.; Kyrtatos, P. G.; Turmaine, M.; Price, A. N.; Pankhurst, Q.; Lythgoe, M. F.; Janes, S. M. Magnetic Resonance Imaging of Mesenchymal Stem Cells Homing to Pulmonary Metastases Using Biocompatible Magnetic Nanoparticles Cancer Res. 2009, 69, 8862-8867 10.1158/0008-5472.CAN-09-1912
31. Olariu, C. I.; Yiu, H. H. P.; Bouffier, L.; Nedjadi, T.; Costello, E.; Williams, S. R.; Halloran, C. M.; Rosseinsky, M. J. Multifunctional Fe3O4 Nanoparticles for Targeted Bi-Modal Imaging of Pancreatic Cancer J. Mater. Chem. 2011, 21, 12650-12659 10.1039/c1jm11370d
32. Xu, Y.; Karmakar, A.; Heberlein, W. E.; Mustafa, T.; Biris, A. R.; Biris, A. S. Multifunctional Magnetic Nanoparticles for Synergistic Enhancement of Cancer Treatment by Combinatorial Radio Frequency Thermolysis and Drug Delivery Adv. Healthcare Mater. 2012, 1, 493-501 10.1002/adhm.201200079
33. Wang, S.; Zhang, Q.; Luo, X. F.; Li, J.; He, H.; Yang, F.; Di, Y.; Jin, C.; Jiang, X. G.; Shen, S. et al. Magnetic Graphene-based Nanotheranostic Agent for Dual-modality Mapping Guided Photothermal Therapy in Regional Lymph Nodal Metastasis of Pancreatic Cancer Biomaterials 2014, 35, 9473-9483 10.1016/j.biomaterials.2014.07.064
34. Lee, G. Y.; Qian, W. P.; Wang, L.; Wang, Y. A.; Staley, C. A.; Satpathy, M.; Nie, S.; Mao, H.; Yang, L. Theranostic Nanoparticles with Controlled Release of Gemcitabine for Targeted Therapy and MRI of Pancreatic Cancer ACS Nano 2013, 7, 2078-89 10.1021/nn3043463
35. Daniel, V. C.; Marchionni, L.; Hierman, J. S.; Rhodes, J. T.; Devereux, W. L.; Rudin, C. M.; Yung, R.; Parmigiani, G.; Dorsch, M.; Peacock, C. D. et al. A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture In vitro Cancer Res. 2009, 69, 3364-3373 10.1158/0008-5472.CAN-08-4210
36. Lefrak, E. A.; Pit'ha, J.; Rosenheim, S.; Gottlieb, J. A. A Clinicopathologic Analysis of Adriamycin Cardiotoxicity Cancer 1973, 32, 302-314 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2
37. Swain, S. M.; Whaley, F. S.; Ewer, M. S. Congestive Heart Failure in Patients Treated with Doxorubicin - A Retrospective Analysis of Three Trials Cancer 2003, 97, 2869-2879 10.1002/cncr.11407
38. Fossella, F. V.; Lippman, S. M.; Shin, D. M.; Tarassoff, P.; CalayagJung, M.; PerezSoler, R.; Lee, J. S.; Murphy, W. K.; Glisson, B.; Rivera, E. et al. Maximum-Tolerated Dose Defined for Single-Agent Gemcitabine: A Phase I Dose-Escalation Study in Chemotherapy-Naive Patients with Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol. 1997, 15, 310-316
39. Batist, G.; Ramakrishnan, G.; Rao, C. S.; Chandrasekharan, A.; Gutheil, J.; Guthrie, T.; Shah, P.; Khojasteh, A.; Nair, M. K.; Hoelzer, K. et al. Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared with Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer J. Clin. Oncol. 2001, 19, 1444-1454
40. Safra, T.; Muggia, F.; Jeffers, S.; Tsao-Wei, D. D.; Groshen, S.; Lyass, O.; Henderson, R.; Berry, G.; Gabizon, A. Pegylated Liposomal Doxorubicin (doxil): Reduced Clinical Cardiotoxicity in Patients Reaching or Exceeding Cumulative Doses of 500 mg/m(2) Ann. Oncol. 2000, 11, 1029-1033 10.1023/A:1008365716693
41. Conroy, T.; Desseigne, F.; Ychou, M.; Bouche, O.; Guimbaud, R.; Becouarn, Y.; Adenis, A.; Raoul, J.-L.; Gourgou-Bourgade, S.; de la Fouchardiere, C. et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer N. Engl. J. Med. 2011, 364, 1817-1825 10.1056/NEJMoa1011923
42. Hidalgo, M.; Von Hoff, D. D. Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas Clin. Cancer Res. 2012, 18, 4249-4256 10.1158/1078-0432.CCR-12-1327
43. Kopetz, S.; Lemos, R.; Powis, G. The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men Clin. Cancer Res. 2012, 18, 5160-5162 10.1158/1078-0432.CCR-12-2408
44. Siolas, D.; Hannon, G. J. Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models Cancer Res. 2013, 73, 5315-5319 10.1158/0008-5472.CAN-13-1069
45. Hylander, B. L.; Pitoniak, R.; Penetrante, R. B.; Gibbs, J. F.; Oktay, D.; Cheng, J. R.; Repasky, E. A. The Anti-tumor Effect of Apo2L/TRAIL on Patient Pancreatic Adenocarcinomas Grown as Xenografts in SCID Mice J. Transl. Med. 2005, 3, 22 10.1186/1479-5876-3-22
46. Julien, S.; Merino-Trigo, A.; Lacroix, L.; Pocard, M.; Goere, D.; Mariani, P.; Landron, S.; Bigot, L.; Nemati, F.; Dartigues, P. et al. Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer Clin. Cancer Res. 2012, 18, 5314-5328 10.1158/1078-0432.CCR-12-0372
47. Tentler, J. J.; Tan, A. C.; Weekes, C. D.; Jimeno, A.; Leong, S.; Pitts, T. M.; Arcaroli, J. J.; Messersmith, W. A.; Eckhardt, S. G. Patient-Derived Tumour Xenografts as Models for Oncology Drug Development Nat. Rev. Clin. Oncol. 2012, 9, 338-350 10.1038/nrclinonc.2012.61
48. Yang, L.; Sajja, H. K.; Cao, Z.; Qian, W.; Bender, L.; Marcus, A. I.; Lipowska, M.; Wood, W. C.; Wang, Y. A. uPAR-targeted Optical Imaging Contrasts as Theranostic Agents for Tumor Margin Detection Theranostics 2014, 4, 106-118 10.7150/thno.7409
49. Harvey, S. R.; Hurd, T. C.; Markus, G.; Martinick, M. I.; Penetrante, R. M.; Tan, D. F.; Venkataraman, P.; DeSouza, N.; Sait, S. N. J.; Driscoll, D. L. et al. Evaluation of Urinary Plasminogen Activator, Its Receptor, Matrix Metalloproteinase-9, and Von Willebrand Factor in Pancreatic Cancer Clin. Cancer Res. 2003, 9, 4935-4943
50. Tan, X. D.; Egami, H.; Nozawa, F.; Abe, M.; Baba, H. Analysis of the Invasion-Metastasis Mechanism in Pancreatic Cancer: Involvement of Lasmin(ogen) Cascade Proteins in the Invasion of Pancreatic Cancer Cells Int. J. Oncol. 2006, 28, 369-374 10.3892/ijo.28.2.369
51. Satpathy, M.; Wang, L.; Zielinski, R.; Qian, W.; Lipowska, M.; Capala, J.; Lee, G. Y.; Xu, H.; Wang, Y. A.; Mao, H. et al. Active Targeting Using HER-2-Affibody-Conjugated Nanoparticles Enabled Sensitive and Specific Imaging of Orthotopic HER-2 Positive Ovarian Tumors Small 2014, 10, 544-555 10.1002/smll.201301593
52. Nasongkla, N.; Bey, E.; Ren, J.; Ai, H.; Khemtong, C.; Guthi, J. S.; Chin, S.-F.; Sherry, A. D.; Boothman, D. A.; Gao, J. Multifunctional Polymeric Micelles as Cancer-Targeted, MRI-Ultrasensitive Drug Delivery Systems Nano Lett. 2006, 6, 2427-2430 10.1021/nl061412u
53. Burke, T. G.; Morin, M. J.; Sartorelli, A. C.; Lane, P. E.; Tritton, T. R. Function of the Anthracycline Amino Group in Cellular Transport and Cytotoxicity Mol. Pharmacol. 1987, 31, 552-556
54. Gabizon, A. A. Pegylated liposomal doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy Cancer Invest. 2001, 19, 424-436 10.1081/CNV-100103136
55. Halford, S.; Yip, D.; Karapetis, C. S.; Strickland, A. H.; Steger, A.; Khawaja, H. T.; Harper, P. G. A Phase II Study Evaluating the Tolerability and Efficacy of CAELYX (Liposomal Doxorubicin, Doxil) in the Treatment of Unresectable Pancreatic Carcinoma Ann. Oncol. 2001, 12, 1399-1402 10.1023/A:1012522120294
56. Lipowska, M.; Patonay, G.; Strekowski, L. New Near-Infrared Cyanine Dyes for Labeling of Proteins Synth. Commun. 1993, 23, 3087-3094 10.1080/00397919308011153